Advances in drug treatment of dyslipidemia: Focus on atorvastatin

Canadian Journal of Cardiology

Volumn 14, Issue SUPPL. B, 1998, Pages

  Davignon, Jean ^a  

^a CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

Author keywords

Atorvastatin; Dyslipidemia; HMG CoA reductase inhibitors; Lipid lowering agents

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN C3; ATORVASTATIN; FIBRIC ACID DERIVATIVE; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LIPOPROTEIN; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PROBUCOL; RESIN; STATINE DERIVATIVE; TRIACYLGLYCEROL;

CONFERENCE PAPER; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DYSLIPIDEMIA; FAMILIAL HYPERCHOLESTEROLEMIA; HUMAN; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; LIPOPROTEIN METABOLISM; PLASMA VISCOSITY; PLEIOTROPY; TRIACYLGLYCEROL BLOOD LEVEL;

ANTICHOLESTEREMIC AGENTS; HEPTANOIC ACIDS; HUMANS; HYPERLIPIDEMIAS; PYRROLES; TRIGLYCERIDES;

EID: 0031835136     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (114)

1. Shepherd J. The West of Scotland Coronary Prevention Study: A trial of cholesterol reduction in Scottish men. Am J Cardiol 1995;76:113C-7C.
2. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
3. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335:1001-9.
4. Blankenhorn DH, Hodis HN. George Lyman Duff Memorial Lecture. Arterial imaging and atherosclerosis reversal. Arterioscler Thromb 1994;14:I77-92.
5. Gotto AM Jr. Lipid risk factors and the regression of atherosclerosis. Am J Cardiol 1995;76:3A-7A.
6. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. The Post Coronary Artery Bypass Graft Trial Investigators. N Engl J Med 1997;336:153-62.
7. Davignon J. Lipid lowering in patients with coronary artery disease: low density lipoprotein cholesterol and beyond. Evidence-based Cardiovasc Med 1997;1:34-5.
8. Davignon J, Cohn JS. Triglycerides: A risk factor for coronary heart disease. Atherosclerosis 1996;(124 Suppl):S57-64.
9. Liao LX, Harris NR, Granger DN. Oxidized low-density lipoproteins and microvascular responses to ischemia-reperfusion. Am J Physiol 1996;271:H2508-14.
10. Gotto AM Jr, Assmann G, Carmena R, Davignon J, Fernandes-Cruz A, Paoletti R. The ILIB Lipid Handbook for Clinical Practice. Blood Lipids and Coronary Heart Disease, 1st edn. Houston: International Lipid Information Bureau, 1995.
11. Davignon J, Montigny M The future of drug therapy for the treatment of dyslipoproteinemia. Acta Angiol 1996;2:11-26.
12. Davignon J. The pleiotropic effect of drugs affecting lipid metabolism. Atherosclerosis 1997;134:103. (Abst)
13. Pasternak RC, Brown LE, Stone PH, Silverman DI, Gibson CM, Sacks FM. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and 'normal' cholesterol levels - A randomized, placebo-controlled trial. Ann Intern Med 1996;125:529-40.
14. Schectman G, Hiatt J. Dose-response characteristics of cholesterol-lowering drug therapies: Implications for treatment. Ann Intern Med 1996;125:990-1000.
15. Brown BG, Bardsley J, Poulin D, et al. Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol <100 mg/dl in patients with hyperlipidemia and coronary artery disease. Am J Cardiol 1997;80:111-5.
16. Davignon J. Fibrates: A review of important issues and recent findings. Can J Cardiol 1994;10:61B-71B.
17. Altschul R, Hoffer A, Stephen MJ. Influence of nicotinic acid on serum cholesterol in man. Arch Biochem Biophys 1955;54:558-9.
18. Rader JI, Calvert RJ, Hathcock JN. Hepatic toxicity of unmodified and time-release preparations of niacin. Am J Med 1992;92:77-81.
19. Davignon J. Probucol. Principles and treatment of lipoprotein disorders. In: Schattler G, ed. Handbook of Experimental Pharmacology, vol 109. Berlin: Springer-Verlag 1994:429-69.
20. Walldius G, Erikson U, Olsson AG, et al. The effect of probucol on femoral atherosclerosis. The Probucol Quantitative Regression Swedish Trial (PQRST). Am J Cardiol 1994;74:875-83.
21. Steinberg D. Clinical trials of antioxidants in atherosclerosis: Are we doing the right thing? Lancet 1995;346:36-8.
22. Tardif JC, Côté G, Lespérance J, et al. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. N Engl J Med 1997;337:365-72.
23. LaRosa J. Review of clinical studies of bile acid sequestrants for lowering plasma lipid levels. Cardiology 1989;76(Suppl 1):55-61.
24. Illingworth DR. Management of hyperlipidemia: Goals for the prevention of atherosclerosis. Clin Invest Med 1990;13:211-8.
25. Farmer JA, Gotto AM Jr. Choosing the right lipid-regulating agent. A guide to selection. Drugs 1996;52:649-61.
26. Grouse JR 3rd. New developments in the use of niacin for treatment of hyperlipidemia. New considerations in the use of an old drug. Coron Artery Dis 1996;7:321-6.
27. Dujovne CA, Krehbiel P, Decoursey S, et al. Probucol with colestipol in the treatment of hypercholesterolemia. Ann Intern Med 1984;100:477-82.
28. Davignon J. Medical management of hyperlipidemia and the role of probucol. Am J Cardiol 1986;57:22H-8H.
29. Davignon J, Roederer G, Montigny M, et al. Comparative efficacy and safety of pravastatin, nicotinic acid and the two combined in patients with hypercholesterolemia. Am J Cardiol 1994;73:339-45.
30. Leitersdorf E, Muratti EN, Eliav O, et al. Efficacy and safety of a combination fluvastatin-bezafibrate treatment for familial hypercholesterolemia: Comparative analysis with a fluvastatin-cholestyramine combination. Am J Med 1994;96:401-7.
31. Athyros VG, Papageorgiou AA, Hatzikonstandinou HA, et al. Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia. Am J Cardiol 1997;80:608-13.
32. Sedaghat A, Ahrens EHJ. Lack of effect of cholestyramine on the pharmacokinetics of clofibrate in man. Eur J Clin Invest 1975;5:177-85.
33. Lehtonen A, Viikari J. Fenofibrate and cholestyramine in type II hyperlipoproteinaemia. Artery 1982;10:353-67.
34. Malmendier CL, Delcroix C, Lontie JF. The effect of combined fenofibrate and cholestyramine therapy on low-density lipoprotein kinetics in familial hypercholesterolemia patients. Clin Chim Acta 1987;162:221-7.
35. Caslake MJ, Packard CJ, Gaw A, et al. Fenofibrate and LDL metabolic heterogeneity in hypercholesterolemia. Arterioscler Thromb 1993;13:702-11.
36. Shepherd J. Mechanism of action of fibrates. Postgrad Med J 1993;69(Suppl 1):S34-41.
37. Schoonjans K, Staels B, Auwerx J. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res 1996;37:907-25.
38. Staels B, Vu-Dac N, Kosykh VA, et al. Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates. J Clin Invest 1995;95:705-12.
39. Hertz R, Bishara-Shieban J, Bar-Tana J Mode of action of peroxisome proliferators as hypolipidemic drugs. Suppression of apolipoprotein C-III. J Biol Chem 1995;270:13470-5.
40. Vu-Dac N, Schoonjans K, Laine B, Fruchart J-C, Auwerx J, Staels B. Negative regulation of the human apolipoprotein A-I promoter by fibrates can be attenuated by the interaction of the peroxisome proliferator-activated receptor with its response element. J Biol Chem 1994;269:31012-8.
41. Berthou L, Duverger N, Emmanuel F, et al. Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice. J Clin Invest 1996;97:2408-16.
42. Kockx M, Princen HMG, Kooistra T. Studies on the role of PPAR in the fibrate-modulated gene expression of apolipoprotein A-I, plasminogen activator inhibitor 1, and fibrinogen in primary hepatocyte cultures from cynomolgus monkey. Ann NY Acad Sci 1996;804:711-2.
43. Berthou L, Saladin R, Yaqoob P, et al. Regulation of rat liver apolipoprotein A-I, apoipoprotein A-II and acyl-coenzyme A oxidase gene expression by fibrates and dietary fatty acids. Eur J Biochem 1995;232:179-87.
44. Staels B, Schoonjans K, Fruchart JC, Auwerx J. The effects of fibrates and thiazolidinediones on plasma triglyceride metabolism are mediated by distinct peroxisome proliferator activated receptors (PPARs). Biochimie 1997;79:95-9.
45. Bruckert E, Dejager S, Chapman MJ. Ciprofibrate therapy normalises the atherogenic low-density lipoprotein subspecies profile in combined hyperlipidemia. Atherosclerosis 1993;100:91-102.
46. Yuan J, Tsai MY, Hunninghake DB. Changes in composition and distribution of LDL subspecies in hypertriglyceridemic and hypercholesterolemic patients during gemfibrozil therapy. Atherosclerosis 1994;110:1-11.
47. Syvänne M, Vuorinen-Markkola H, Hilden H, Taskinen M-R. Gemfibrozil reduces postprandial lipemia in non-insulin-dependent diabetes mellitus. Arterioscler Thromb 1993;13:286-95.
48. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: A meta-analysis and review of the literature. Ann Intern Med 1993;118:956-63.
49. Fujii S, Sobel BE. Direct effects of gemfibrozil on the fibrinolytic system. Diminution of synthesis of plasminogen activator inhibitor type I. Circulation 1992;85:1888-93.
50. Branchi A, Rovellini A, Sommariva D, Gugliandolo AG, Fasoli A. Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen levels in patients with primary hypercholesterolemia. Thromb Haemost 1993;70:241-3.
51. Niort G, Bulgarelli A, Cassader M, Pagano G. Effect of short term treatment with bezafibrate on plasma fibrinogen, fibrinopeptide A, platelet activation and blood filterability in atherosclerotic hyperfibrinogenemic patients. Atherosclerosis 1988;71:113-9.
52. Simpson IA, Lorimer AR, Walker ID, Davidson JF. Effect of ciprofibrate on platelet aggregation and fibrinolysis in patients with hypercholesterolaemia. Thromb Haemost 1985;54:442-4.
53. Leschke M, Hoffken H, Schmidtsdorff A, et al. [The effect of fenofibrate on fibrinogen concentration and blood viscosity: its possible consequence for myocardial microcirculation in coronary heart disease]. Dtsch Med Wochenschr 1989;114:939-44.
54. Wilkes HC, Meade TW, Barzegar S, et al. Gemfibrozil reduces plasma prothrombin fragment F1 + 2 concentration, a marker of coagulability, in patients with coronary heart disease. Thromb Haemost 1992;67:503-6.
55. Knipscheer HC, De Valois J, Van den Ende B, Ten Cate JW, Kastelein JJP. Ciprofibrate versus gemfibrozil in the treatment of primary hyperlipidaemia. Atherosclerosis 1996;124:S75-81.
56. De Maat MPM, Knipscheer HC, Kastelein JJP, Kluft C. Modulation of plasma fibrinogen levels by ciprofibrate and gemfibrozil in primary hyperlipidaemia. Thromb Haemost 1997;77:75-9.
57. Athyros VG, Papageorgiou AA, Avramidis MJ, Kontopoulos AG. Long-term effect of gemfibrozil on coronary heart disease risk profile of patients with primary combined hyperlipidaemia. Coron Artery Dis 1995;6:251-6.
58. Nordt TK, Kornas K, Peter K, et al. Attenuation by gemfibrozil of expression of plasminogen activator inhibitor type 1 induced by insulin and its precursors. Circulation 1997;95:677-83.
59. Ishiwata S, Nakanishi S, Nishiyama S, Seki A. Prevention of restenosis by bezafibrate after successful coronary angioplasty. Coron Artery Dis 1995;6:883-9.
60. Haite WD. Gemfibrozil predictably lowers triglycerides but does not significantly change plasminogen activator inhibitor activity in hypertriglyceridernic patients with a history of thrombosis. Thromb Res 1991;64:493-501.
61. Broijersén A, Eriksson M, Wiman B, Angelin B, Hjemdahl P. Gemfibrozil treatment of combined hyperlipoproteinemia. No improvement of fibrinolysis despite marked reduction of plasma triglyceride levels. Arterioscler Thromb Vasc Biol 1996; 16:511-6.
62. Levinson HZ, Levinson AR. Insectistatic action of the lipid antagonist ethyl-p-chlorophenoxyisobutyrate. Naturwissenschaften 1973;60:1-3.
63. Steinhart WL, Hogeman CS, Powanda MC. Inhibition of the production of infectious herpes simplex virus by clofibrate. Virology 1976;70:241-3
64. De Gennes JL, Bertrand C, Bigorie B, Truffert J. Première démonstration de l'activité antidiurétique, pharmacologique et thérapeutique du clofibrate (atromid-S) dans le diabète insipide. C R Acad Sci Paris 1969;269:2607-10.
65. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors and incidence of coronary heart disease. N Engl J Med 1987;317:1237-45.
66. Ericsson C-G, Hamsten A, Nilsson J, Grip L, Svane B, De Faire U. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 1996;347;849-53.
67. Ericsson CG, Nilsson J, Grip L, Svane B, Hamsten A. Effect of bezafibrate treatment after five years on coronary plaques causing 20% to 50% diameter narrowing (The Bezafibrate Coronary Atherosclerosis Intervention Trial [BECAIT]). Am J Cardiol 1997;80:1125-9.
68. Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Am J Cardiol 1992;70:733-7.
69. Davignon J, Montigny M, Dufour R. HMG-CoA reductase inhibitors: A look back and a look ahead. Can J Cardiol 1992;8:843-64.
70. Illingworth DR, Tobert JA. A review of clinical trials comparing HMG-CoA reductase inhibitors. Clin Ther 1994;16:366-85.
71. Lennernäs H, Fager G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Clin Pharmacokinet 1997;32:403-25.
72. Pierce LR, Wysowski DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA 1990;264:71-5.
73. Garnett WR. Interactions with hydroxymerhylglutaryl-coemyme A reductase inhibitors. Am J Health Syst Pharm 1995;52:1639-45.
74. Neuvonen PJ, Jalava KM. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 1996;60:54-61.
75. Hebert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA 1997;278:313-21.
76. Werner RM, Pearson TM. LDL-cholesterol: A risk factor for coronary artery disease - from epidemiology to clinical trials. Can J Cardiol 1998;14(Suppl B):3B-10B.
77. Davignon J, Xhignesse M, Mailloux H, et al. Comparative study of lovastatin versus probucol in the treatment of hypercholesterolemia. Atheroscler Rev 1988;18:139-51.
78. Pan HY, DeVault AR, Swites BJ, et al. Pharmacokinetics and pharmacodynamics of pravastatin alone and with cholestyramine in hypercholesterolemia. Clin Pharmacol Ther 1990;48:201-7.
79. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7.
80. Gould KL, Martucci JP, Goldberg DI, et al. Short-term cholesterol lowering decreases size and severity of perfusion abnormalities by positron emission tomography after dipyridamole in patients with coronary artery disease: A potential noninvasive marker of healing coronary endothelium. Circulation 1994;89.1530-8.
81. Egashira K, Hirooka Y, Kai H, et al. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation 1994;89:2519-24.
82. Treasure CB, Klein JL, Weintraub WS, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995;332:481-7.
83. Eichstädt HW, Eskötter H, Hoffmann I, Amthauer HW, Weidinger G. Improvement of myocardial perfusion by short-term fluvastatin therapy in coronary artery disease. Am J Cardiol 1995;76(Suppl):122A-5A.
84. Vogel RA, Corretti MC, Plotnick GD. Changes in flow-mediated brachial artery vasoactivity with lowering of desirable cholesterol levels in healthy middle-aged men. Am J Cardiol 1996;77:37-40.
85. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 1995;332:488-93.
86. Anderson TJ, Meredith IT, Charbonneau F, et al. Endothelium-dependent coronary vasomotion relates to the susceptibility of LDL to oxidation in humans. Circulation 1996;93.1647-50.
87. Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995;333:621-7.
88. Wenke K, Meiser B, Thiery J, et al. Simvastatin reduces graft vessel disease and mortality after heart transplantation, a four year randomized trial. Circulation 1997;96:1398-402.
89. Lacoste L, Lam JYT, Hung J, Letchacovski G, Solymoss CB, Waters D. Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction. Circulation 1995;92:3172-7.
90. Lacoste L, Lam JYT. Comparative effect of pravastatin and simvastatin on platelet-thrombus formation in hypercholesterolemic coronary patients. J Am Coll Cardiol 1996;27:413A. (Abst)
91. Soma MR, Donetti E, Parolini C, et al. HMG CoA reductase inhibitors: In vivo effects on carotid intimai thickening in normocholesterolemic rabbits. Arterioscler Thromb 1993;13:571-8.
92. Corsini A, Raiteri M, Soma MR, Bernini F, Fumagalli R, Paoletti R. Pathogenesis of atherosclerosis and the role of 3-hydroxy- 3-methylglutaryl coenzyme A reductase inhibitors. Am J Cardiol 1995;76 (Suppl):21A-8A.
93. Nègre-Aminou P, Van Vliet AK, Van Erck M, Van Thiel GCF, Van Leeuwen REW, Cohen LH. Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors: Comparison with other human cell types. Biochim Biophys Acta 1997;1345:259-68.
94. Igarashi M, Takeda Y, Mori S, et al. Suppression of neointimal thickening by a newly developed HMG-CoA reductase inhibitor, BAYw6228 and its inhibitory effect on vascular smooth muscle cell growth. Br J Pharmacol 1997;120:1172-8.
95. Giroux LM, Davignon J, Naruszewicz M. Simvastatin inhibits the oxidation of low-density lipoproteins by activated human monocyte- derived macrophages. Biochim Biophys Acta 1993;1165:335-8.
96. Davignon J. Atorvastatin: a statin with a large spectrum of action. Atheroscler ID Res Alert 1997,2:233-52.
97. Black DM. Atorvastatin: a step ahead for HMG-CoA reductase inhibitors. In: Woodford FP, Davignon J, Sniderman A, eds. Atherosclerosis X. Amsterdam: Elsevier Science BV, 1995:307-10.
98. Jacotot B, Benghozi R, Pfister P, Holmes D. Comparison of fluvastatin versus pravastatin treatment of primary hypercholesterolemia. Am J Cardiol 1995;76(Suppl)54A-6A.
99. Nawrocki JW, Weiss SR, Davidson MH, et al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb 1995;15:678-82.
100. Davidson MH, Stein EA, Dujovne CA, et al. The efficacy of six-week tolerability of simvastatin 80 and 160 mg/day. Am J Cardiol 1997;79:38-42.
101. Arad Y, Ramakrishnan R, Ginsberg HN. Lovastatin therapy reduces low density lipoprotein apoB levels in subjects with combined hyperlipidemia by reducing the production of apoB-containing lipoproteins: Implications for the pathophysiology of apoB production. J Lipid Res 1990;31:567-82.
102. Bakker-Arkema RG, Davidson MH, Goldstern RJ, et al. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglycendemia. JAMA 1996;275:128-33.
103. Ooi TC, Heinonen T, Alaupovic P, et al. Efficacy and safety of a new hydroxymethylglutaryl-coenzyme a reductase inhibitor, atorvastatin, in patients with combined hyperlipidemia: Comparison with fenofibrate. Artenoscler Thromb Vasc Biol 1997;17:1793-9.
104. Heinonen TM, Schrott H, McKenney JM, et al. Atorvastatin, a new HMG-CoA reductase inhibitor as monotherapy and combined to colestipol. J Cardiovasc Pharmacol Ther 1996;1:117-22.
105. Marais AD, Firth JC, Bateman ME, Byrnes P, Martens C, Mountney J. Atorvastatin: An effective lipid-modifying agent in familial hypercholesterolemia Arterioscler Thromb Vasc Biol 1997;17:1527-31.
106. Soma M, Piliego T, Seregni R, Donetti E, Paoletti R, Fumagalli R. Effect of atorvastatin in intimai carotid thickening induced by perivascular maniputaion in normocholesterolemic rabbits. 66th Congress of the European Atherosclerosis Society, Florence, July 13 to 17, 1996:231.
107. Alfon J, Pueyo AF, Badimon L. Regulation by atorvastatin, a novel HMG-CoA reductase inhibitor, of plasma lipids and thrombotic risk in atherosclerotic rabbits. 66th Congress of the European Atherosclerosis Society, Florence, July 13 to 17, 1996:201. (Abst)
108. Negre-Aminou P, vanErck M, Cohen LH. Antiproliferative potencies of 6 vastatins in cultured human cells; involvement of the RAS-mediated signalling pathway. 66th Congress of the European Atherosclerosis Society, Florence, July 13 to 17, 1996:120. (Abst)
109. Dujovne CA, Harris WS, Altman R, Overhiser RW, Cunningham JJ, Black DM. Changes in hemorheology and atherothrombotic parameters by improving serum lipids in atorvastatin-treated hyperlipidemics. 66th Congress of the European Atherosclerosis Society, Florence, July 13 to 17, 1996:169. (Abst)
110. Hackman A, Abe Y, Insull W Jr, et al. Levels of soluble cell adhesion molecules in patients with dyslipidemia. Circulation 1996;93:1334-8.
111. Huang Q, Alvares K, Chu R, Bradfield CA, Reddy JK. Association of peroxisome proliferator-activated receptor and Hsp72. J Biol Chem 1994;269:8493-7.
112. Hertz R, Bishara-Shieban J, Bar-Tana J. Mode of action of peroxisome proliferators as hypolipidemic drugs. Suppression of apolipoprotein C-III. J Biol Chem 1995;270:13470-75.
113. Franceschini G, Sirtori CR. Fibrates and the concept of fraudulent fatty acids. In: Woodford FP, Davignon J, Sniderman A, eds. Atherosclerosis X. New York: Elsevier Science BV, 1995:325-9.
114. Brown MS, Goldstein JL. How LDL receptors influence cholesterol and atherosclerosis. Sci Am 1984;251:58-66.